Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year –– 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million –– Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million –– Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter and full-year 2025 results and recent business performance.“In 2025, LINZESS delivered 11% EUTRx demand growth year-over-year, continuing to strengt
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
- Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highlights: Strong LINZESS Sales and ... [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call [Yahoo! Finance]Yahoo! Finance
IRWD
Earnings
- 2/25/26 - Miss
IRWD
Sec Filings
- 2/26/26 - Form 10-K
- 2/25/26 - Form 4
- 2/25/26 - Form 4
- IRWD's page on the SEC website